Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.
Zacks Investment Research8/20/2026Positive
MGNX
MacroGenics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$280.28M
P/E Ratio
—
EPS
$-1.59
Beta
1.23
52W High
$5.08
52W Low
$1.29
50-Day MA
$4.20
200-Day MA
$3.02
Dividend Yield
—
Profit Margin
-8.33%
Forward P/E
60.98
PEG Ratio
0.01
About MacroGenics Inc
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
Fundamentals
| Revenue (TTM) | $175.14M |
| Gross Profit (TTM) | $-1.30M |
| EBITDA | $-32.17M |
| Operating Margin | -42.20% |
| Return on Equity | -225.90% |
| Return on Assets | -8.05% |
| Revenue/Share (TTM) | $2.76 |
| Book Value | $0.67 |
| Price-to-Book | 6.31 |
| Price-to-Sales (TTM) | 1.60 |
| EV/Revenue | 0.757 |
| EV/EBITDA | 5.57 |
| Quarterly Earnings Growth (YoY) | -70.40% |
| Quarterly Revenue Growth (YoY) | 378.00% |
| Shares Outstanding | $63.70M |
| Float | $57.01M |
| % Insiders | 3.48% |
| % Institutions | 77.54% |
Historical Volatility
HV 10-Day
52.34%
HV 20-Day
46.32%
HV 30-Day
50.44%
HV 60-Day
63.15%
HV Rank
2.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($8.00 target)
1
Strong Buy2
Buy4
HoldLatest News
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended June 30, 2026, and highlighted its recent corporate and pipeline progress.
GlobeNewsWire8/13/2026Neutral
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program
ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under the companies' 2022 collaboration agreement. The option exercise triggers a $10 million payment to MacroGenics.
GlobeNewsWire8/11/2026Neutral
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important
MacroGenics is affirmed as a 'Buy' due to a de-risked operational runway and promising B7-H3 ADC pipeline asset. MGNX's pipeline is refocused after setbacks; cash infusions and divestitures extend the runway through 2028, trading near liquid value. MGC026, the B7-H3 ADC, shows no major safety issues and will present data in late 2026, offering potential upside if efficacy emerges.
Seeking Alpha7/27/2026Positive
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research7/2/2026Positive
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, today announced completion of the sale of MacroGenics' good manufacturing practice (GMP) drug substance manufacturing operations to Bora.
GlobeNewsWire7/2/2026Neutral
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on Wednesday, May 20, 2026 at 10:30 a.m. ET.
GlobeNewsWire5/14/2026Neutral
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
ROCKVILLE, Md., May 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended March 31, 2026, and highlighted its recent corporate progress.
GlobeNewsWire5/13/2026Neutral
Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research5/5/2026Negative
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million • MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million
GlobeNewsWire5/4/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MGNX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026